Phaseline

Targets › AAK1

AAK1 (AP2-associated protein kinase 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Neurology; next expected readout Mar 2027.

Regulates clathrin-mediated endocytosis by phosphorylating the AP2M1/mu2 subunit of the adaptor protein complex 2 (AP-2) which ensures high affinity binding of AP-2 to cargo membrane proteins during the initial stages of endocytosis. Isoform 1 and isoform 2 display similar levels of kinase activity towards AP2M1. (UniProt, Q2M2I8)

Open in Phaseline: the race on AAK1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Satellos BioscienceSAT-3247
AAK1 inhibitor that promotes functional rescue of asymmetric satellite cell division
AAK1Phase 2Duchenne Muscular DystrophyMar 2027

Conditions

Duchenne Muscular Dystrophy (1)

Modalities

small molecule (1)

Companies

Satellos Bioscience (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.